Literature DB >> 19053086

Synthesis and structure-activity relationships of ferrocenyl tamoxifen derivatives with modified side chains.

Anh Nguyen1, Siden Top, Pascal Pigeon, Anne Vessières, Elizabeth A Hillard, Marie-Aude Plamont, Michel Huché, Clara Rigamonti, Gérard Jaouen.   

Abstract

We report here the synthesis and cell-proliferation properties of derivatives of the breast cancer drug tamoxifen, in which the -O(CH(2))(2)N(CH(3))(2) side chain, responsible for the drug's antiestrogenic properties, has been modified by a ferrocenyl moiety. We recently reported the diphenol compound 5, in which this amino chain had been replaced with an acyl-ferrocenyl (-O(CH(2))(2)C(O)[(eta(5)-C(5)H(4))FeCp]) group, and which showed antiproliferative effects against both the hormone-dependent MCF-7 and -independent MDA-MB-231 breast cancer cell lines. We now report the results of a structure-activity relationship (SAR) study, in which the lateral chain length has been varied, the ketone group has been omitted, and the number of phenol groups has been varied. Compounds 1-4, with a side chain lacking the carbonyl function (-O(CH(2))(n)[(eta(5)-C(5)H(4))FeCp], n = 1-4) and which show a decreasing affinity for ERalpha (ER = estrogen receptor) with increasing chain length, act as estrogens on MCF-7 cells, and mild cytotoxics on PC-3 prostate cancer cells, with IC(50) values around 10 microM. The two monophenolic derivatives of 2, 2 a and 2 b, which show a reduced affinity for ERalpha compared to 2, are also estrogenic, but are only slightly cytotoxic. Finally, we have reexamined compound 5 and discovered that its antiproliferative effect against the MCF-7 cell line does not arise from antiestrogenicity as we had originally suspected, but by means of a cytotoxic pathway. This compound is also sensitive to the number of phenol groups as cell death is diminished when one of the hydroxyl groups is omitted (5 a and 5 b). Molecular modeling studies of the ligand-ERalpha binding stability are broadly consistent with the experimental binding affinity results for compounds 2, 2 a, 2 b, 5, 5 a, and 5 b. Electrochemical experiments show that 1-4, 2 a, and 2 b are stable to oxidation on the electrochemical timescale, unlike 5, 5 a, and 5 b, and that cytotoxicity is related to less positive phenol oxidation potentials. The SAR study shows that the presence of a ketone group and two phenol groups is necessary for strong receptor binding and cytotoxic effects, and that all compounds are estrogenic, despite the presence of a bulky side chain.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19053086     DOI: 10.1002/chem.200801108

Source DB:  PubMed          Journal:  Chemistry        ISSN: 0947-6539            Impact factor:   5.236


  9 in total

1.  Design and synthesis of norendoxifen analogues with dual aromatase inhibitory and estrogen receptor modulatory activities.

Authors:  Wei Lv; Jinzhong Liu; Todd C Skaar; David A Flockhart; Mark Cushman
Journal:  J Med Chem       Date:  2015-03-09       Impact factor: 7.446

2.  Ferrocenes as potential chemotherapeutic drugs: synthesis, cytotoxic activity, reactive oxygen species production and micronucleus assay.

Authors:  Wanda I Pérez; Yarelys Soto; Carmen Ortíz; Jaime Matta; Enrique Meléndez
Journal:  Bioorg Med Chem       Date:  2014-12-19       Impact factor: 3.641

3.  Development of selective estrogen receptor modulator (SERM)-like activity through an indirect mechanism of estrogen receptor antagonism: defining the binding mode of 7-oxabicyclo[2.2.1]hept-5-ene scaffold core ligands.

Authors:  Yangfan Zheng; Manghong Zhu; Sathish Srinivasan; Jerome C Nwachukwu; Valerie Cavett; Jian Min; Kathryn E Carlson; Pengcheng Wang; Chune Dong; John A Katzenellenbogen; Kendall W Nettles; Hai-Bing Zhou
Journal:  ChemMedChem       Date:  2012-04-19       Impact factor: 3.466

4.  Functionalized ferrocenes: The role of the para substituent on the phenoxy pendant group.

Authors:  José L Vera; Jorge Rullán; Natasha Santos; Jesús Jiménez; Joshua Rivera; Alberto Santana; Jon Briggs; Arnold L Rheingold; Jaime Matta; Enrique Meléndez
Journal:  J Organomet Chem       Date:  2014-01-01       Impact factor: 2.369

Review 5.  Current applications and future potential for bioinorganic chemistry in the development of anticancer drugs.

Authors:  Sabine H van Rijt; Peter J Sadler
Journal:  Drug Discov Today       Date:  2009-09-24       Impact factor: 7.851

Review 6.  Organometallic anticancer compounds.

Authors:  Gilles Gasser; Ingo Ott; Nils Metzler-Nolte
Journal:  J Med Chem       Date:  2010-11-15       Impact factor: 7.446

7.  Crystal structure of bis-[4-(1H-pyrrol-1-yl)phen-yl] ferrocene-1,1'-di-carboxyl-ate: a potential chemotherapeutic drug.

Authors:  Wanda I Pérez; Arnold L Rheingold; Enrique Meléndez
Journal:  Acta Crystallogr E Crystallogr Commun       Date:  2015-04-22

8.  Metal complexes of benzimidazole-derived as potential anti-cancer agents: synthesis, characterization, combined experimental and computational studies.

Authors:  Van-Thanh Nguyen; Thi-Kim-Chi Huynh; Gia-Thien-Thanh Ho; Thi-Hong-An Nguyen; Thi Le Anh Nguyen; Duy Quang Dao; Tam V T Mai; Lam K Huynh; Thi-Kim-Dung Hoang
Journal:  R Soc Open Sci       Date:  2022-09-21       Impact factor: 3.653

9.  Harmicens, Novel Harmine and Ferrocene Hybrids: Design, Synthesis and Biological Activity.

Authors:  Goran Poje; Marina Marinović; Kristina Pavić; Marija Mioč; Marijeta Kralj; Lais Pessanha de Carvalho; Jana Held; Ivana Perković; Zrinka Rajić
Journal:  Int J Mol Sci       Date:  2022-08-18       Impact factor: 6.208

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.